Condition: Chronic Lymphocytic Leukemia (CLL) · Small Lymphocytic Lymphoma (SLL) · Diffuse Large B Cell Lymphoma (DLBCL) · Sponsor: Nurix Therapeutics, Inc.
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
This description comes directly from the study's public registry record.
Additional Site Contact Information · +1 (415) 417-3418 · clinicaltrials@nurixtx.com
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| National Institute of Health | Bethesda, Maryland, United States | Recruiting |
| Cayuga Medical Center | Ithaca, New York, United States | Withdrawn |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Active Not Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
+ 50 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05131022